Future of convection-enhanced delivery in the treatment of brain tumors

Future Oncology

Volumn 6, Issue 1, 2010, Pages 117-125

  Bidros, Dani S ^a   Liu, James K ^a   Vogelbaum, Michael A ^b  

^a NEUROLOGICAL INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Brain neoplasm; Convection enhanced delivery; Drug delivery system

Indexed keywords

AP 12009; CARMUSTINE; CINTREDEKIN BESUDOTOX; COTARA; IMMUNOTOXIN; INTERLEUKIN 13; INTERLEUKIN 4(38-37); MONOCLONAL ANTIBODY; NBI 3001; PACLITAXEL; PRX 321; PSEUDOMONAS EXOTOXIN; TEMOZOLOMIDE; TOPOTECAN; TP 38; TRANSFERRIN CRM107; TRANSFORMING GROWTH FACTOR BETA; TRANSMID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONVECTION ENHANCED DELIVERY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GLIOBLASTOMA; GLIOMA; HUMAN; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; CONVECTION; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS;

EID: 75149112409     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.135     Document Type: Review

References (46)

1. Gralow J, Ozols RF, Bajorin DF et al.: Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J. Clin. Oncol. 26(2), 313-325 (2008).
2. Dandy WE: Removal of right cerebral hemisphere for certain tumors with hemiplegia. JAMA 90, 823-825 (1928).
3. Bobo RH, Laske DW, Akbasak A et al.: Convection-enhanced delivery of macromolecules in the brain. Proc. Natl Acad. Sci. USA 91(6), 2076-2080 (1994). ■■ First article to describe the use of low, continuous, positive pressure infusion for the delivery of drugs and other macromolecules into the brain, and includes a mathematical description of the convection process.
4. Hall WA, Sherr GT: Convection-enhanced delivery of targeted toxins for malignant glioma. Expert Opin. Drug Deliv. 3, 371-377 (2006).
5. Raghavan R, Brady ML, Rodriquez-Ponce MI, Hartlep A, Pedain C, Sampson JH: Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg. Focus 20(4), E12 (2006).
6. Laske DW, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat. Med. 3(12), 1362-1368 (1997). ■ One of the first reports to show the potential clinical benefit associated with convection-enhanced delivery (CED) of a targeted therapeutic molecule for the treatment of patients with gliomas.
7. Weaver M, Laske DW: Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J. Neurooncol. 65(1), 3-13 (2003).
8. Patel SJ, Shapiro WR, Laske DW et al.: Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 56(6), 1243-1252 (2005).
9. Debinski W, Obiri NI, Pastan I, Puri RK: A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J. Biol. Chem. 270(28), 16775-16780 (1995).
10. Puri RK, Mehrotra PT, Lelan P, Kreitman RJ, Siegel JP, Pastan I: A chimeric protein comprised of IL-4 and Pseudomonas exotoxin is cytotoxic for activated human lymphocytes. J. Immunol. 152(7), 3693-3700 (1994).
11. Kawakami M, Kawakami K, Puri RK: Interleukin-4-pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. J. Neurooncol. 65(1), 15-25 (2003).
12. Rand RW, Keritman RJ, Patronas N, Varricchio F, Pastan I, Puri RK: Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin. Cancer Res. 6(6), 2157-2165 (2000).
13. Weber FW, Floeth F, Asher A et al.: Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001)for treatment of patients with recurrent malignant glioma. Acta Neurochir. Supp. 88, 93-103 (2003).
14. Weber F, Asher A, Bucholz R et al.: Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J. Neurooncol. 64(1-2), 125-137.
15. Mardor Y, Last D, Daniels D et al.: Convection enhanced delivery of IL-4 Pseudomonas exotoxin (PRX321): increased distribution and MR monitoring. J. Pharmacol. Exp. Ther. 330(2), 520-525 (2009).
16. Sampson JH, Akabani G, Archer GE et al.: Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol. 10, 320-329 (2008).
17. Kunwar S, Prados MD, Chang SM et al.: Intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J. Clin. Oncol. 25(7), 837-844 (2007).
18. Sampson JH, Raghavan R, Provenzale JM et al.: Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumortargeted cytotoxin. AJR Am. J. Roentgenol. 188(3), 703-709 (2007).
19. Sampson JH, Brady ML, Petry NA et al.: Intracerebral infusated distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery 60 (2 Suppl. 1), ONS89-ONS98 (2007).
20. Sampson JH, Raghavan R, Brady ML et al.: Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol. 9(3), 343-353 (2007). ■ Demonstrates the first use of a patientspecific, computationally-based predictive model of drug distribution by CED in the clinical setting.
21. Kunwar S, Westphal M, Medhorn M et al.: Results from PRECISE: a randomized Phase 3 study in patients with first recurrent glioblastoma multiforme (GBM) comparing cintredekin besudotox (CB) administered via convection-enhanced delivery (CED) with gliadel wafers (GW). Presented at: 12th Annual Meeting of the Society for Neuro-Oncology, 15-18 November 2007, Dallas, TX, USA. ■■ Documents the results of the first completed Phase III trial for the treatment of glioblastoma with use of CED.
22. Vogelbaum MA, Sampson JH, Kunwar S et al.: Convection-enhanced delivery of cintredekin besudotox (interleuking-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: Phase 1 study of final safety results. Neurosurgery 61(5), 1031-1037 (2007).
23. Lidar Z, Mardor Y, Jonas T et al.: Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a Phase I/II clinical study. J. Neurosurg. 100, 472-479 (2004).
24. Bruce JN, Fine RL, Canoll P, Sisti MB et al.: Phase I trial of topotecan by convection enhanced delivery for recurrent malignant gliomas. Presented at: 2009 AANS National Meeting. 2-6 May 2009, Chicago, IL, USA.
25. Schlingensiepen KH, Fischer-Blass B, Schmaus, S et al.: Antisense therapeutics for tumor treatment: the TGF-b 2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res. 177, 137-150 (2008).
26. Vallera DA, Li Chunbin, Jin N, Panoskaltsis-Mortari A, Hall WA: Targeting urokinasetype plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J. Natl Cancer Inst. 94(8), 597-606 (2002).
27. Hall WA, Vallera DA: Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme. Neurosurg. Focus 20(4), E23 (2006).
28. Rustamzadeh E, Hall WA, Todhunter DA et al.: Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice. Int. J. Cancer 120(2), 411-419 (2007).
29. Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH: Convectionenhanced distribution of large molecules in gray matter during interstitial drug infusion. J. Neurosurg. 82, 1021-1029 (1995).
30. Morrison PF, Chen MY, Chadwick RS, Lonser RR, Oldfield EH: Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics. Am. J. Physiol. 277, 1218-1229 (1999). ■■ Describes many of the issues we continue to face regarding the catheter-brain interface and avoidance of backflow and infusate 'dumping' into cerebrospinal fluid spaces.
31. Krauze MT, Saito R, Noble C et al.: Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J. Neurosurg. 103, 923-929 (2005). ■ One of the earliest descriptions of a novel catheter design that may help overcome the problem of infusate backflow (reflux) around the infusion catheter.
32. Oh S, Odland R, Wilson S et al.: Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J. Neurosurg. 107, 568-577 (2007).
33. Grahn AY, Bankiewicz KS, Dugich-Djordjevic M et al.: Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. J. Neurooncol. 95(2), 185-197 (2009).
34. Huwyler J, Wu D, Pardridge WM: Brain drug delivery of small molecules using immunoliposomes. Proc. Natl Acad. Sci. USA 93, 14164-14169 (1996).
35. Kreuter J: Nanoparticles: In: Encyclopedia of pharmaceutical technology (Volume 10). Swarbrick J, Boylan JC (Eds). Marcel Dekker, NY, USA, 165-190 (1994).
36. Gelperina SE, Smirnova ZS, Khalanskiy AS, Skidan IN, Bobruskin AI, Kreuter J: Chemotherapy of brain tumors using doxorubicin bound to polysorbate 80-coated nanoparticles. Proceedings of the 3rd World Meeting APV/APGI. Berlin, Germany 2000. 3-6 April 2000, 441-442 (2003).
37. Rogawski MA: Convection-enhanced delivery in the treatment of epilepsy. Neurotherapeutics 6, 344-351 (2009).
38. Varenika V, Dickinson P, Bringas, J et al.: Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. J. Neurosurg. 109, 874-880 (2008).
39. Mardor Y, Rahav O, Zauberman Y et al.: Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring. Cancer Res. 65, 6858-6863 (2005).
40. Krauze MT, Forsayeth J, Park JW, Bankiewicz KS: Real-time imaging and quantification of brain delivery of liposomes. Pharm. Res. 23, 2493-2504 (2006).
41. Krauze MT, McKnight TR, Yamashita Y et al.: Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res. Protoc. 16, 20-26 (2005). ■■ Demonstrates the value of co-infusion of an imaging tracer with a therapeutic molecule to document the extent of drug delivery in the brain. This approach will allow for documentation of treatment 'isodoses' within the target tissue.
42. Saito R, Krauze MT, Bringas JR et al.: Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp. Neurol. 196, 381-389 (2005).
43. Croteau D, Walbridge S, Morrison PF et al.: Real-time in vivo imaging of the convective distribution of a low-molecular-weight tracer. J. Neurosurg. 102, 90-97 (2005).
44. Mardor Y, Roth Y, Lidar Z et al.: Monitoring response to convectionenhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res. 61, 4971-4973 (2001).
45. Regino CA, Walbridge S, Bernardo M et al.: A dual CT-MR dendrimer contrast agent as a surrogate marker for convection-enhanced delivery of intracerebral macromolecular therapeutic agents. Contrast Media Mol. Imaging 3, 2-8 (2008).
46. Voges J, Reszka R, Gossmann A et al.: Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann. Neurol. 54, 479-487 (2003) ■ Demonstrates that co-infusion directly into the brain of a commonly used, gadolinium- based MRI contrast agent is safe in humans and can document the delivery of a therapeutic agent.